242 related articles for article (PubMed ID: 36875550)
1. Trial watch: Toll-like receptor ligands in cancer therapy.
Le Naour J; Kroemer G
Oncoimmunology; 2023; 12(1):2180237. PubMed ID: 36875550
[TBL] [Abstract][Full Text] [Related]
2. Trial Watch: Toll-like receptor agonists in cancer immunotherapy.
Smith M; García-Martínez E; Pitter MR; Fucikova J; Spisek R; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2018; 7(12):e1526250. PubMed ID: 30524908
[TBL] [Abstract][Full Text] [Related]
3. Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.
Iribarren K; Bloy N; Buqué A; Cremer I; Eggermont A; Fridman WH; Fucikova J; Galon J; Špíšek R; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2016 Mar; 5(3):e1088631. PubMed ID: 27141345
[TBL] [Abstract][Full Text] [Related]
4. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.
Chakraborty S; Ye J; Wang H; Sun M; Zhang Y; Sang X; Zhuang Z
Front Immunol; 2023; 14():1227833. PubMed ID: 37936697
[TBL] [Abstract][Full Text] [Related]
5. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.
Engel AL; Holt GE; Lu H
Expert Rev Clin Pharmacol; 2011 Mar; 4(2):275-89. PubMed ID: 21643519
[TBL] [Abstract][Full Text] [Related]
7. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
Lee SN; Jin SM; Shin HS; Lim YT
Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor agonists as cancer vaccine adjuvants.
Jeon D; Hill E; McNeel DG
Hum Vaccin Immunother; 2024 Dec; 20(1):2297453. PubMed ID: 38155525
[TBL] [Abstract][Full Text] [Related]
9. Trial Watch: Toll-like receptor agonists in oncological indications.
Aranda F; Vacchelli E; Obrist F; Eggermont A; Galon J; Sautès-Fridman C; Cremer I; Henrik Ter Meulen J; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014; 3():e29179. PubMed ID: 25083332
[TBL] [Abstract][Full Text] [Related]
10. Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists.
Andón FT; Leon S; Ummarino A; Redin E; Allavena P; Serrano D; Anfray C; Calvo A
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884895
[TBL] [Abstract][Full Text] [Related]
11. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
13. In vivo cancer vaccination: Which dendritic cells to target and how?
Chiang CL; Kandalaft LE
Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.
Baxevanis CN; Voutsas IF; Tsitsilonis OE
Immunotherapy; 2013 May; 5(5):497-511. PubMed ID: 23638745
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic and therapeutic implications of toll-like receptor ligands.
Hedayat M; Takeda K; Rezaei N
Med Res Rev; 2012 Mar; 32(2):294-325. PubMed ID: 22383179
[TBL] [Abstract][Full Text] [Related]
16. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
17. TLR Agonists as Adjuvants for Cancer Vaccines.
Li JK; Balic JJ; Yu L; Jenkins B
Adv Exp Med Biol; 2017; 1024():195-212. PubMed ID: 28921471
[TBL] [Abstract][Full Text] [Related]
18. Use of adjuvants for immunotherapy.
Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
20. Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.
Frega G; Wu Q; Le Naour J; Vacchelli E; Galluzzi L; Kroemer G; Kepp O
Oncoimmunology; 2020 Jul; 9(1):1796002. PubMed ID: 32934889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
